192 related articles for article (PubMed ID: 7877976)
21. Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model.
Tseng YL; Hong RL; Tao MH; Chang FH
Int J Cancer; 1999 Mar; 80(5):723-30. PubMed ID: 10048974
[TBL] [Abstract][Full Text] [Related]
22. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
23. Targeting her-2/neu with antirat Neu virosomes for cancer therapy.
Waelti E; Wegmann N; Schwaninger R; Wetterwald A; Wingenfeld C; Rothen-Rutishauser B; Gimmi CD
Cancer Res; 2002 Jan; 62(2):437-44. PubMed ID: 11809693
[TBL] [Abstract][Full Text] [Related]
24. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma.
Brignole C; Marimpietri D; Gambini C; Allen TM; Ponzoni M; Pastorino F
Cancer Lett; 2003 Jul; 197(1-2):199-204. PubMed ID: 12880982
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
Shepard HM; Lewis GD; Sarup JC; Fendly BM; Maneval D; Mordenti J; Figari I; Kotts CE; Palladino MA; Ullrich A
J Clin Immunol; 1991 May; 11(3):117-27. PubMed ID: 1679763
[TBL] [Abstract][Full Text] [Related]
27. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells.
Zhu Z; Lewis GD; Carter P
Int J Cancer; 1995 Jul; 62(3):319-24. PubMed ID: 7628874
[TBL] [Abstract][Full Text] [Related]
28. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.
Nam SM; Kim HS; Ahn WS; Park YS
Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027
[TBL] [Abstract][Full Text] [Related]
29. Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells.
Burks SR; Macedo LF; Barth ED; Tkaczuk KH; Martin SS; Rosen GM; Halpern HJ; Brodie AM; Kao JP
Breast Cancer Res Treat; 2010 Nov; 124(1):121-31. PubMed ID: 20066490
[TBL] [Abstract][Full Text] [Related]
30. Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency.
Srinivas U; Tagliabue E; Campiglio M; Ménard S; Colnaghi MI
Cancer Immunol Immunother; 1993 Jun; 36(6):397-402. PubMed ID: 8098992
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
J Clin Oncol; 1996 Mar; 14(3):737-44. PubMed ID: 8622019
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.
Nielsen UB; Kirpotin DB; Pickering EM; Hong K; Park JW; Refaat Shalaby M; Shao Y; Benz CC; Marks JD
Biochim Biophys Acta; 2002 Aug; 1591(1-3):109-118. PubMed ID: 12183061
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells.
Suzuki S; Uno S; Fukuda Y; Aoki Y; Masuko T; Hashimoto Y
Br J Cancer; 1995 Sep; 72(3):663-8. PubMed ID: 7669578
[TBL] [Abstract][Full Text] [Related]
34. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
35. Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours.
Manjappa AS; Goel PN; Gude RP; Ramachandra Murthy RS
J Drug Target; 2014 Sep; 22(8):698-711. PubMed ID: 24766186
[TBL] [Abstract][Full Text] [Related]
36. 186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts.
Kotts CE; Su FM; Leddy C; Dodd T; Scates S; Shalaby MR; Wirth CM; Giltinan D; Schroff RW; Fritzberg AR; Shepard HM; Slamon DJ; Hutchins BM
Cancer Biother Radiopharm; 1996 Apr; 11(2):133-44. PubMed ID: 10851530
[TBL] [Abstract][Full Text] [Related]
37. Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing.
Gao J; Sun J; Li H; Liu W; Zhang Y; Li B; Qian W; Wang H; Chen J; Guo Y
Biomaterials; 2010 Mar; 31(9):2655-64. PubMed ID: 20035999
[TBL] [Abstract][Full Text] [Related]
38. Development of anti-HB-EGF immunoliposomes for the treatment of breast cancer.
Nishikawa K; Asai T; Shigematsu H; Shimizu K; Kato H; Asano Y; Takashima S; Mekada E; Oku N; Minamino T
J Control Release; 2012 Jun; 160(2):274-80. PubMed ID: 22020380
[TBL] [Abstract][Full Text] [Related]
39. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity.
Gao J; Kou G; Wang H; Chen H; Li B; Lu Y; Zhang D; Wang S; Hou S; Qian W; Dai J; Zhao J; Zhong Y; Guo Y
Breast Cancer Res Treat; 2009 May; 115(1):29-41. PubMed ID: 18481173
[TBL] [Abstract][Full Text] [Related]
40. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.
Lewis GD; Figari I; Fendly B; Wong WL; Carter P; Gorman C; Shepard HM
Cancer Immunol Immunother; 1993 Sep; 37(4):255-63. PubMed ID: 8102322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
